Skip to main content

Table 2 Biochemistry

From: Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study

Parameter Placebo Apabetalone P value
HbA1c
 Baseline (%) 7.3 (6.4–8.6) 7.4 (6.4–8.7)  
 Follow up (%) 7.2 (6.4–8.4) 7.2 (6.4–8.5)  
 Absolute change (%) 0.00 [− 0.10, 0.05] − 0.05 [− 0.15, 0.00] 0.18
 Percent change (%) 0.04 [− 0.76, 0.88] − 0.63 [− 1.49, 0.25] 0.25
LDL-C
 Baseline (mg/dL) 70.9 ± 32.4 69.7 ± 29.8  
 Follow up (mg/dL) 63.6 ± 29.4 63.4 ± 28.3  
 Absolute change (mg/dL) − 6.55 [− 8.00, − 5.10] − 6.34 [− 7.79, − 4.89] 0.37
 Percent change (%) − 0.31 [− 4.13, 3.50] − 1.57 [− 2.25, 5.38] 0.28
HDL-C
 Baseline (mg/dL) 33.3 ± 5.1 33.3 ± 5.1  
 Follow up (mg/dL) 36.6 ± 7.5 38.0 ± 8.0  
 Absolute change (mg/dL) 3.34 [2.93, 3.75] 4.75 [4.34, 5.15] < 0.0001
 Percent change (%) 10.9 [9.62, 12.2] 15.4 [14.1, 16.7] < 0.0001
hsCRP
 Baseline (mg/L) 2.7 (1.1–6.1) 2.9 (1.3–5.9)  
 Follow up (mg/L) 1.8 (1.0–4.3) 1.8 (0.9–3.9)  
 Absolute change (mg/L) − 0.53 [− 0.93, − 0.24] − 0.80 [− 1.3, − 0.44] 0.34
 Percent change (%) − 11.3 [− 20.0, − 1.5] − 18.4 [− 28.0, − 7.1] 0.16
ALP
 Baseline (U/L) 81.9 ± 34.7 83.3 ± 38.2  
 Follow up (U/L) 79.5 ± 29.5 74.3 ± 43.2  
 Absolute change (U/L) − 2.20 [− 3.60, − 0.81] − 8.98 [− 10.4, − 7.59] < 0.0001
 Percent change (%) 4.22 [0.27, 8.18] − 8.31 [− 12.2, − 4.37] < 0.0001
eGFR
 Baseline (mL/min) 102 ± 38.6 105 ± 39.2  
 Follow up (mL/min) 105 ± 40.2 106 ± 41.9  
 Absolute change (mL/min) 2.02 [0.97, 3.07] − 0.33 [− 1.38, 1.72] 0.001
 Percent change (%) 3.03 [1.87, 4.18] − 0.46 [− 0.70, 1.61] 0.001
  1. Biochemical parameters at baseline and change after 24 weeks (12 weeks for CRP) of treatment with apabetalone or placebo. Baseline means ± SDs or medians (IQR) are shown. For absolute and percent change, estimates with [95% CIs] are given
  2. ALP alkaline phosphatase, HbA1c glycated haemoglobin, HDL-C high-density lipoprotein cholesterol, hsCRP high-sensitivity C-reactive protein (assessed in only a subset of patients), LDL-C low-density lipoprotein cholesterol, eGFR estimated glomerular filtration rate